April 2005

How Patients Can Benefit From Molecular Imaging

Paula M. Jacobs, Ph.D

Vice President

Advanced Magnetics, Inc

April 2005

How Patients Can Benefit From Molecular Imaging

• Probe basic biological and disease processes in animal models– Identify therapeutic targets

– Identify prognostic factors

• Provide new clinical imaging agents for– Diagnosis

– Therapeutic stratification

– Monitor response to therapy

April 2005

MR Agent Development

• $50 M minimum and at least 10 years to develop a single diagnostic indication

• Reimbursement now around $45/dose

• Might be able to charge $100-200/dose

• About 1 million patients a year to even think about breaking even

• Example: 10-12,000 new high grade glioma patients each year

April 2005

Barriers to clinical availability of imaging

agents• Small potential patient populations but

ever increasing regulatory requirements

• Expensive pre-clinical & manufacturing investment before trials

• Unpredictable regulatory climate

• Difficult reimbursement climate

Poor commercial viability

April 2005

What can we do to make these targeted imaging agents

available to small but important patient

populations?